Efficacy of Rituximab in Acute Cellular Rejection With B-cell Infiltrates in Renal Transplant Patients - Randomized Placebo Controlled Double Blind Trial

Trial Profile

Efficacy of Rituximab in Acute Cellular Rejection With B-cell Infiltrates in Renal Transplant Patients - Randomized Placebo Controlled Double Blind Trial

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Rituximab (Primary) ; Corticosteroids
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms RIACT
  • Most Recent Events

    • 20 May 2016 Status changed from active, no longer recruiting to discontinued.
    • 01 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 10 May 2012 Planned End Date changed from 1 May 2014 to 1 May 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top